Pharmaceutical Intermediates Deferasirox for Hemochromatosis CAS 201530-41-8
GMP HALAL KOSHER ISO FDA 2 Inquiries
201530-41-8
Pharmaceutical Grade
99%
Foil Bag, Box, Drum
2022-12-31
Herb Extracts,Cosmetic raw materails,API
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
Product DescriptionProduct Name: Deferasirox
Synonyms: 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid;deferasirox;Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-;Deferasirox for research;4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid;CGP-72670;Exjade;ICL-670
CAS: 201530-41-8
MF: C21H15N3O4
MW: 373.3615
Product Categories: Chelating agent (iron);Aromatics Compounds;Aromatics;Chelating Agents & Ligands;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;Exjade, ICL-670, ICL-670A, CGP-72670
Melting point 260-262ºC
Storage temp. -20°C Freezer
Chemical Properties White to Off-White Solid
Usage Orally active tridentate iron chelator
Usage Biological Activity Chemical Information Tech Support & FAQs Biological Activity Deferasirox(Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions
Usage A tridentate chelator that binds iron with high affinity .
Usage Labeled Deferasirox, intended for use as an internal standard for the quantification of Deferasirox by GC- or LC-mass spectrometry.
Deferasirox: chemical name 4- [3,5-bis (2-hydroxyphenyl) -1,2,4-triazol-1-yl] benzoic acid, is a kind of iron chelator products studied and developed by the Novartis company (Swiss). It was the first routinely used oral iron agent approved by US FDA, allowed to be applied for the treatment of iron overloading caused by blood transfusion in patients (older than 2 years old) of chronic anemia. In Europe, it is recommended as the first-line treatment drug for patients older than 6-year-old who are suffering blood iron overload patients.
In China, it is currently subject to clinical research; 2, 3 clinical trials and pharmacokinetic studies have all shown that it has excellent safety and tolerability, and can significantly reduce the heart, liver iron load, easy to be accepted by the patient. At the same time, it also has pharmacological properties of antifungal (such as Mucor which can grow in iron-ricking environment), anti-cell proliferation, anti-malaria, antioxidant stress injury and anti-cytotoxicity induced apoptosis; it can be used for the treatment of hemochromatosis, delayed skin porphyria and other diseases.
Application
1. DFS can be used to treat the reversible renal insufficiency caused by Fanconi syndrome.
2. It can be used for the treatment of secondary hemochromatosis.
3. It can be used for the treatment of delayed skin porphyria.
4. It can be used for the treatment of myelodysplastic syndromes.
5. It can be used for the treatment of iron overloading caused by blood transfusion for patients (older than 2 years old) of chronic anemia .
Product Photo
CertificatesBasic Info-
Product Name:
Deferasirox
Other Name:Benzoic acid,4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-;4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid;ICL 670A;ICL 670;Deferasirox;4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid;Exjade;Asunra;Jadenu
CAS No.:201530-41-8
Molecular Formula:C21H15N3O4
InChIKeys:InChIKey=BOFQWVMAQOTZIW-UHFFFAOYSA-N
Molecular Weight:373.3615
Exact Mass:373.36
EC Number:1806241-263-5
UNII:V8G4MOF2V9
DSSTox ID:DTXSID1048596
NCI Thesaurus Code:C48384
Color/Form:Crystals from ethanol|White to slightly yellow powder
ATC Code:V03AC03|V - Various
HScode:2933990090
Categories:
Characteristics-
PSA:
109 Ų
XLogP3:log Kow = 6.30 (pH 7.4)|3.52
Density:1.4±0.1 g/cm3
Melting Point:260-2620C
Boiling Point:651°C at 760 mmHg
Flash Point:360.3±34.3 °C
Refractive Index:1.699
Water Solubility:In water, 0.4 mg/mL at 25 °C (pH 7.40)|3.43e-02 g/L
Storage Conditions:-20°C Freezer
Vapor Pressure:1.67X10-13 mm Hg at 25 °C (est)
Henrys Law Constant:Henry's Law constant = 1.4X10-17 atm-cu m/mol at 25 °C (est)
Dissociation Constants:pKa1 = 4.57; pKa2 = 8.71; pKa3 = 10.56|Dissociation constant also reported in H2O/DMSO (X(DMSO = 0.20) as pKa1 = 4.61; pKa2 = 10.12; pKa3 = 12.08
Experimental Properties:Hydroxyl radical reaction rate constant = 2.05X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H410 Very toxic to aquatic life with long lasting effects
Precautionary statement(s) Prevention P273 Avoid release to the environment.
Response P391 Collect spillage.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Herb Extracts,Cosmetic raw materails,API
-
Location:
1403,Jinye B Block
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
8
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
India
Deferasirox
25 KG Mar 19, 2024 
Hongkong, China
Deferasirox is an iron chelator (binder)
5000 KG May 12, 2025 Post an enquiry for this product